Systematic review shows incretin therapies reduce binge eating and address obesity, suggesting further trials are needed.
GLP-1 RAs may offer dual therapeutic benefits for BED, reducing binge eating behaviors while addressing comorbid obesity and metabolic consequences. However, available evidence is limited by small sample sizes, heterogeneous methods, and short follow-up durations. Larger randomized controlled trials using standardized diagnostic criteria and validated psychiatric measures are warranted.
No takes yet. Share an insight, caveat, or question.
White et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: